Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3199 vs Formoterol in Asthma
NCT00736489Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2008
- Primary completion
- Dec 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of AZD3199 in asthma (6 arms), sponsored by AstraZeneca. Primary endpoints: FEV1 Peak Effect Within 0 - 24 h Post-dose, Average FEV1 Value Between 22 and 26 h Post Dose and 2 more. Started Aug 2008; status: completed.
02
Drugs
AZD3199
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00736489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00736489.